8-K: DocGo Q2 Revenue Halves Amid Migrant Program Wind-Down

DocGo Inc. reported a significant revenue decline and net loss in Q2 2025 due to the planned wind-down of migrant-related programs, while reiterating full-year guidance and highlighting growth in core services.

Summary

• Total revenue for Q2 2025 was $80.4 million, a substantial decrease from $164.9 million in Q2 2024, primarily due to the planned wind-down of migrant-related programs.
• The company reported a net loss of $13.3 million for Q2 2025, compared to a net income of $5.9 million in Q2 2024.
• Adjusted EBITDA was a loss of $6.1 million in Q2 2025, down from a positive adjusted EBITDA of $17.2 million in Q2 2024.
• GAAP gross margin declined to 26.7% in Q2 2025 from 31.3% in Q2 2024, and adjusted gross margin decreased to 31.6% from 33.9%.
• Mobile Health Services revenue fell to $30.8 million in Q2 2025 from $116.7 million in Q2 2024, also due to migrant program wind-down.
• Transportation Services revenue saw a slight increase to $49.6 million in Q2 2025 from $48.2 million in Q2 2024.
• Total cash and cash equivalents, including restricted cash and investments, increased to $128.7 million as of June 30, 2025, from $103.1 million as of March 31, 2025.
• DocGo repurchased 2.5 million shares of common stock for approximately $5.1 million during Q2 2025.
• Cash flow from operations was $33.6 million in Q2 2025, compared to $36.9 million in Q2 2024.
• The company reiterated its full-year 2025 revenue guidance of $300-$330 million and adjusted EBITDA loss guidance of $20-$30 million.
• Subsequent to quarter end, the company paid down $30 million on its line of credit, bringing the outstanding balance to $0.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While current financial results show a significant decline in revenue and a shift to net loss/EBITDA loss due to the planned wind-down of migrant programs, the company demonstrated strong cash generation, increased cash reserves, executed share repurchases, and secured new contracts in its core mobile health and transportation segments. Management's reiterated guidance and clear path to profitability by H2 2026, coupled with ongoing cost-cutting, suggest a positive long-term outlook despite short-term headwinds.

Positives

• Total cash and cash equivalents, including restricted cash and investments, increased significantly to $128.7 million as of June 30, 2025, up from $103.1 million as of March 31, 2025.
• The company repurchased 2.5 million shares of common stock for approximately $5.1 million during Q2 2025, indicating confidence in valuation.
• DocGo surpassed 1.2 million patients assigned for care gap closure services, an increase from 900,000 last quarter, demonstrating growth in core payer and provider business.
• Launched a new care gap closure program in Southern California with a major not-for-profit Medicare and Medicaid public health plan.
• Expanded care gap closure relationship with a major insurance company in the Northeast to include primary care services.
• Launched a project with the Mescalero Apache Tribe and the New Mexico Department of Health to expand access to preventive wellness care in rural communities.
• Recognized as a top healthcare employer in U.S. News & World Report's 2025-2026 Best Companies to Work For.
• Renewed a contract with the City of Atlantic City for 911 basic life support services.
• Subsequent to quarter end, the company paid down $30 million on its line of credit, resulting in a $0 outstanding balance.
• Launched services under a multi-year contract with a large academic medical system in the New York metro area for dedicated ambulance services and discharge transportation.
• Management identified and implemented cuts to corporate overhead, resulting in an estimated $10 million in annual SG&A savings, with further reductions planned.

Negatives

• Total revenue for Q2 2025 significantly declined to $80.4 million from $164.9 million in Q2 2024, primarily due to the planned wind-down of migrant-related programs.
• The company reported a net loss of $13.3 million in Q2 2025, a shift from a net income of $5.9 million in Q2 2024.
• Adjusted EBITDA shifted to a loss of $6.1 million in Q2 2025, compared to a positive adjusted EBITDA of $17.2 million in Q2 2024.
• GAAP gross margin decreased to 26.7% in Q2 2025 from 31.3% in Q2 2024.
• Adjusted gross margin decreased to 31.6% in Q2 2025 from 33.9% in Q2 2024.
• Mobile Health Services revenue saw a substantial decline to $30.8 million in Q2 2025 from $116.7 million in Q2 2024, driven by the migrant program wind-down.

Risks

• Impacts related to the accelerated wind-down of migrant-related services.
• Uncertainties related to future non-migrant municipal population health revenue.
• Ability to return to profitability and/or expand programs with insurance partners, hospital systems, municipalities, and other strategic partners.
• Ability to successfully implement business strategy, including delivering value to shareholders via buybacks, funding new strategic relationships, and potentially repaying its line of credit.
• Ability to establish, maintain, and grow customer relationships.
• Ability to execute projects to the satisfaction of customers.
• Ability to grow demand for care gap closure programs.
• Ability to maintain or grow cash balances.
• Reliance on and ability to maintain contractual relationships with healthcare provider partners and other strategic partners.
• Ability to compete effectively in a highly competitive industry, including conditions in the healthcare transportation and mobile health services markets.
• Ability to maintain existing contracts.
• Reliance on government contracts, including changes in government spending on healthcare and other social services.
• Recent revenue growth derived from a small number of large customers.
• Ability to effectively manage growth.
• Financial performance and future prospects.
• Workforce reduction and ability to achieve associated cost savings.
• Ability to deliver on business strategies or models, plans, and goals.
• Ability to expand geographically.
• M&A activity and success of its acquisition strategy.
• Ability to retain its workforce and management personnel and successfully manage leadership transitions.
• Availability of healthcare professionals and other personnel; changes in the cost of labor.
• Ability to collect on customer receivables, particularly the remaining $54 million in migrant-related receivables.
• Risks associated with the share repurchase program.
• Overall macroeconomic and geopolitical conditions, including interest rate environment, inflationary environment, potential recessionary environment, regional conflict and tensions, financial institution instability, and prospect of a U.S. federal government shutdown.
• Ability of suppliers to meet its needs.
• Ability to obtain or maintain operating licenses.
• Potential changes in federal, state, or local government policies or priorities.
• Expected impacts of geopolitical instability.
• Competitive position and opportunities, including its ability to realize the benefits from its operating model.
• Ability to improve gross margins.
• Ability to implement and deliver on cost-containment measures and ongoing cost rationalization initiatives.
• Legislative and regulatory actions.
• Impact of legal proceedings and compliance risk.
• Volatility of stock price.
• Impact on the business and reputation in the event of information technology system failures, network disruptions, cyber incidents, or losses or unauthorized access to, or release of, confidential information.
• Ability to comply with laws and regulations regarding data privacy and protection.

Future Outlook

DocGo reiterated its full-year 2025 revenue guidance of $300-$330 million and adjusted EBITDA loss guidance of $20-$30 million. Management anticipates entering more than a half dozen new states in the payer and provider vertical by the end of 2026. They expect the new medical transportation customer in New York to drive highest-ever revenues and trip volumes in that vertical during the second half of 2025. The company aims to achieve profitability in the second half of 2026 through continued SG&A reductions, right-sizing staffing levels, and aggressive vendor cost management, coupled with anticipated growth.

Management Comments

• "We continue to make substantial progress expanding our payer and provider business and building a strong foundation for the future."
• "During the quarter we surpassed 1.2 million patients assigned for care gap closure services and completed more in-home visits in the first half of 2025 than we did in the entirety of 2024."
• "We anticipate entering more than a half dozen new states in this vertical by the end of 2026."
• "Additionally, we launched services for a major new medical transportation customer in the New York market on July 1st, which we expect will help drive our highest-ever revenues and trip volumes in this vertical during the second half of the year."
• "Our total cash balance increased substantially to $128.7 million during the quarter as we continue to collect on our migrant related receivables."
• "Our combined outstanding migrant-related receivables now total approximately $54 million, and we continue to believe that those amounts will be collected over the remainder of the year."
• "We also made considerable progress reducing our SG&A during the quarter, making cuts to corporate overhead that will result in an estimated $10 million in annual savings."
• "We believe that continuing to right-size our staffing levels and aggressively managing our vendor costs, coupled with our strong pipeline and anticipated growth, will enable us to achieve profitability in the second half of 2026."

Industry Context

DocGo operates in the evolving mobile health and medical transportation sectors, which are increasingly focused on proactive, in-home care and efficient patient transport. The company's strategy to expand its payer and provider partnerships for 'care gap closure' and primary care services aligns with broader industry trends towards value-based care, preventative health, and reducing hospital readmissions. The growth in its transportation segment, coupled with new contracts with academic medical systems, indicates a strong position in a critical, often overlooked, aspect of healthcare logistics. The wind-down of migrant-related programs, while impacting current revenue, allows the company to re-focus on its core, higher-margin, and more sustainable business lines, which is a strategic move in a competitive healthcare landscape.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess DocGo's performance against global benchmarks. The focus is on internal financial metrics and strategic growth initiatives.

Legal Proceedings

• The company lists 'impact of legal proceedings and compliance risk' as a general risk factor, but no specific ongoing litigation or regulatory matters are detailed in the filing.

Stakeholder Impact

• Shareholders: Experience current financial losses and revenue decline, but benefit from share repurchases and potential for future profitability and growth in core businesses.
• Employees: Subject to workforce reductions as part of cost-saving initiatives.
• Customers: New and expanded contracts indicate continued and growing service provision, particularly in care gap closure and medical transportation.
• Creditors: The company paid down its line of credit to $0, improving its financial position with lenders.
• Suppliers: The company identifies the ability of its suppliers to meet its needs as a risk factor.

Next Steps

• Continue collecting on approximately $54 million in outstanding migrant-related receivables over the remainder of 2025.
• Implement concrete steps in Q3 and Q4 2025 to further reduce SG&A base by right-sizing staffing levels and aggressively managing vendor costs.
• Achieve profitability in the second half of 2026.
• Enter more than a half dozen new states in the payer and provider vertical by the end of 2026.

Key Dates

Recommendation

The company is undergoing a significant transition, winding down a high-revenue but temporary migrant program while strategically expanding its core mobile health and medical transportation services. While Q2 2025 financial results show a substantial decline in revenue and a shift to net loss, this was largely anticipated due to the planned program wind-down. Positives include a strong cash position, share repurchases, new contract wins, and aggressive cost-cutting measures, with management reiterating guidance and projecting profitability by H2 2026. The current financial performance is weak, but the strategic direction and underlying business growth in core areas suggest potential for future recovery. Therefore, a 'hold' recommendation is appropriate for investors to observe the execution of the strategic pivot and the realization of projected profitability.

Keywords

Mobile Health, Medical Transportation, Healthcare Services, Telehealth, Care Gap Closure, Ambulance Services, Q2 Earnings, Financial Results, SEC Filing, DCGO, DocGo